2024-520148-40-00已完成1 期
First time in human clinical test using a personalized tissue-engineered blood vessel to treat chronical illness in a vein.
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- VeriGraft AB
- 入组人数
- 15
- 试验地点
- 11
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
Raimund Strehl
Scientific
VeriGraft AB
研究点 (11)
Loading locations...
相似试验
尚未招募
1 期
Phase 1, first-in-human trial to evaluate the safety, tolerability, and pharmacokinetics of ascending single oral doses of octreotide/ LipOra-Peptide in healthy volunteersAcromegalyDRKS00032263niversität Heidelberg vertreten durch das Universitätsklinikum95
招募中
1 期
Investigator-initiated, first-in-human trial of non-virally engineered GMR CAR T cells against CD116-positive acute myeloid leukemia and juvenile myelomonocytic leukemia.CD116-positive acute myeloid leukemia and juvenile myelomonocytic leukemiaJPRN-jRCT2033210029akazawa Yozo21
尚未招募
1 期
A study to test different doses of BI 764532 in patients with small cell lung cancer and other neuroendocrine tumours that are positive for DLL3.Small cell lung carcinoma and neuroendocrine carcinomaJPRN-jRCT2080225308Boehringer Ingelheim19
招募中
1 期
First in human pilot study to assess the safety and efficacy of dendritic cells loaded with frameshift derived neopeptides for the prevention of cancer in Lynch Syndrome carriers2025-521109-42-00Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer20
已完成
1 期
First-In-Human Pilot Study to Demonstrate the Safety and the Performance of the Cardiac Microcurrent Therapy System (CMIC System)I50.9Heart failure, unspecifiedDRKS00015708Berlin Heals GmbH10